Organizational profile: UK regenerative medicine platform immunomodulation hub

The UK Regenerative Medicine Platform was launched in 2013 as a jointly funded venture by the Biotechnology and Biological Sciences Research Council (BBSRC), Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Counci...

Full description

Saved in:
Bibliographic Details
Published in:Regenerative medicine 2015-05, Vol.10 (3), p.259-263
Main Author: Asante, Curtis O
Format: Article
Language:English
Subjects:
Adaptive Immunity
cell therapy
Cell- and Tissue-Based Therapy - methods
Cell- and Tissue-Based Therapy - trends
Cellular therapy
Humans
Immunity, Innate
Immunology
Immunomodulation
regenerative medicine
Regenerative Medicine - methods
Regenerative Medicine - organization & administration
Regenerative Medicine - trends
stem cells
United Kingdom
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The UK Regenerative Medicine Platform was launched in 2013 as a jointly funded venture by the Biotechnology and Biological Sciences Research Council (BBSRC), Biotechnology and Biological Sciences Research Council, Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Council (MRC) to address the technical and scientific challenges associated with translating promising scientific discoveries into the clinical setting. The first stage of the Platform involved the establishment of five interdisciplinary and cross-institutional research Hubs and the final Hub, the Immunomodulation Hub, was formed in 2014. The Immunomodulation Hub comprises scientists from diverse clinical and nonclinical research backgrounds. Collectively, they provide expertise in tissues for which there is an unmet clinical need for regenerative treatments, in innate and adaptive immunity and in whole organ transplantation. Their vision is that by working together to determine how regenerative medicine cell therapies in a laboratory setting are affected by the immune system, they will make a substantial contribution to long-term clinical deliverables that include improved efficacy of photoreceptor cell therapy to treat blindness; improved repair of damaged heart tissue; and improved survival and functionality of transplanted hepatocytes as an alternative to liver transplantation.
ISSN:1746-0751
1746-076X
DOI:10.2217/rme.15.16